Table 5. Profile of treatment-related toxicities.

	IC/CCRT (n = 321)	IC/RT (n = 321)	P
Grade 3-4 adverse events during IC, n (%)
Hematological
Leukopenia/neutropenia	100 (31%)	106 (33%)	0.672
Thrombocytopenia	16 (5%)	13(4%)	0.704
Anemia	13(4%)	10 (3%)	0.671
Non-hematological
Stomatitis (mucositis)	5(1.6%)	3(1%)	0.722
Nausea/ vomiting	55(17%)	48(15%)	0.519
Diarrhea	8 (2.5%)	11 (3.5%)	0.641
Liver dysfunction	3(1%)	2(0.6%)	1.000
Kidney dysfunction	0	0	1.000
Grade 3-4 adverse events during RT, n (%)
Hematological
Leukopenia/neutropenia	39(12%)	6(1.9%)	0.000
Thrombocytopenia	28(9%)	4(1.2%)	0.000
Anemia	12(3.7%)	2(0.6%)	0.015
Non-hematological
Skin reaction (radiation-related)	22(7%)	16(5%)	0.403
Mucositis (radiation-related)	157(49%)	96(30%)	0.000
Nausea /vomiting	77(24%)	9(3%)	0.000
Dry mouth	102(32%)	87(27%)	0.225
Grade 3-4 late toxicities, n (%)
Cranial neuropathy	14 (4.5%)	16 (5%)	0.708
Temporal lobe necrosis	22 (7%)	29 (9%)	0.307
Ear (deafness/otitis)	132 (41%)	119(37%)	0.293
Neck tissue damage	80 (25%)	67 (21%)	0.222

IC, induction chemotherapy; CCRT, concurrent chemoradiotherapy; RT: radiotherapy.

P-values were calculated using the Chi-square test (or Fisher's exact test if the expected number was < 5 in at least 25% of cells).